Industry
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Loading...
Open
106.10
Mkt cap
486B
Volume
8M
High
107.73
P/E Ratio
36.73
52-wk high
148.15
Low
105.59
Div yield
0.01
52-wk low
94.73
Portfolio Pulse from Shanthi Rexaline
June 21, 2023 | 3:17 pm
Portfolio Pulse from Vandana Singh
June 20, 2023 | 5:49 pm
Portfolio Pulse from Happy Mohamed
June 20, 2023 | 2:32 pm
Portfolio Pulse from Vandana Singh
June 20, 2023 | 1:07 pm
Portfolio Pulse from Vandana Singh
June 20, 2023 | 12:44 pm
Portfolio Pulse from Charles Gross
June 20, 2023 | 8:42 am
Portfolio Pulse from Aaron Bry
June 16, 2023 | 6:31 pm
Portfolio Pulse from Benzinga Insights
June 16, 2023 | 5:37 pm
Portfolio Pulse from Vandana Singh
June 14, 2023 | 1:34 pm
Portfolio Pulse from Benzinga Insights
June 12, 2023 | 4:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.